US Bancorp DE Reduces Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

US Bancorp DE lessened its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,019 shares of the company's stock after selling 2,107 shares during the period. US Bancorp DE owned about 0.27% of Axsome Therapeutics worth $11,086,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. FMR LLC grew its position in Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company's stock worth $97,786,000 after purchasing an additional 185,951 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company's stock valued at $81,659,000 after acquiring an additional 23,564 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Axsome Therapeutics by 1.1% during the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock worth $66,750,000 after acquiring an additional 8,125 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Axsome Therapeutics by 4.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company's stock worth $28,992,000 after purchasing an additional 12,778 shares during the last quarter. Finally, Loomis Sayles & Co. L P boosted its holdings in shares of Axsome Therapeutics by 11.0% in the 3rd quarter. Loomis Sayles & Co. L P now owns 298,586 shares of the company's stock worth $26,834,000 after buying an additional 29,497 shares during the last quarter. Institutional investors own 81.49% of the company's stock.

Remove Ads

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM traded down $2.24 during trading hours on Friday, reaching $122.17. 509,828 shares of the stock traded hands, compared to its average volume of 1,028,148. The company's 50-day simple moving average is $108.07 and its two-hundred day simple moving average is $97.47. The company has a market capitalization of $5.96 billion, a P/E ratio of -20.40 and a beta of 0.99. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AXSM. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price objective for the company. William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, February 19th. StockNews.com upgraded shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Finally, Royal Bank of Canada raised their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $167.36.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.